Fieldview Capital Management’s NewAmsterdam Pharma NAMS Stock Holding History

Fieldview Capital Management’s Portfolio NAMS Stock Details NAMS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.42M	Buy	+41,842	New	+$1.38M	0.4%	48

Other funds holding NAMS

FLSM

Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

FIS

FCPM III Services Naarden, Netherlands $750M AUM 127.27% 1-Year Est. Return

Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

BCLSI

Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return

Maverick Capital Dallas, Texas $11.3B AUM 76.6% 1-Year Est. Return

DFO

Duquesne Family Office New York $5.21B AUM 87.01% 1-Year Est. Return

Fieldview Capital Management's NAMS Position: Q2 2026 in Review

Fieldview Capital Management opened a new position in NewAmsterdam Pharma (NAMS) in Q2 2026: 41,842 shares worth $1.42M. The stake represents 0.4% of the portfolio and ranks #48 among its holdings.

194 funds tracked by Wall St. Rank hold NAMS as of Q2 2026.

Fieldview Capital Management held 41,842 shares of NewAmsterdam Pharma worth $1.42M as of Q2 2026.
NewAmsterdam Pharma was a new Fieldview Capital Management position in Q2 2026.
NewAmsterdam Pharma made up 0.4% of Fieldview Capital Management's portfolio in Q2 2026, its #48 holding.
194 funds tracked by Wall St. Rank held NewAmsterdam Pharma as of Q2 2026.

Based on Fieldview Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.